A chemically defined, toleragen-based approach for targeting anti-β2-glycoprotein I antibodies
Authors:
- 1 February 1998
- journal article
- review article
- Published by SAGE Publications in Lupus
- Vol. 7 (2_suppl) , 166-229
Abstract
Antiphospholipid syndrome is characterized by a prothrombotic state and the presence of β2-glycoprotein I (β2-GPI)-dependent antiphospholipid antibodies. The feasibility of a B cell tolerance-based approach for specific reduction of anti-β2-GPI antibodies was investigated. Anti-β2GPI antibodies isolated from a patient with antiphospholipid syndrome were used to screen peptide libraries expressed in phage, resulting in the identification of a phage that specifically bound anti-β2-GPl antibodies. The phage-displayed peptide was identified and chemically optimized to generate a synthetic 14-mer peptide with an internal thioether linkage (LJP 685) that retained the binding profile of the original phage. LJP 685 was conjugated to a defined, non-immunogenic organic platform to generate a tetravalent presentation of LJP 685 for use as a toleragen. Tetravalent LJP 685 induced a dose-dependent reduction in antibody levels in mice previously immunized and boosted with LJP 685 coupled to the carrier keyhole limpet hemocyanin. These experiments support the technical feasibility of a tolerance-based approach for reducing anti-β2GPI antibodies in vivo.Keywords
This publication has 9 references indexed in Scilit:
- Differential Effects of Anti–β2-Glycoprotein I and Antiprothrombin Antibodies on the Anticoagulant Activity of Activated Protein CBlood, 1998
- Differential Effects of Anti–β 2 -Glycoprotein I Antibodies on Endothelial Cells and on the Manifestations of Experimental Antiphospholipid SyndromeCirculation, 1998
- The Role of the Tissue Factor Pathway in the Hypercoagulable State in Patients with the Antiphospholipid SyndromeThrombosis and Haemostasis, 1998
- IgG Anticardiolipin Antibody Titer >40 GPL and the Risk of Subsequent Thrombo-occlusive Events and DeathStroke, 1997
- A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice.Proceedings of the National Academy of Sciences, 1996
- THE LUPUS ANTICOAGULANT/ANTIPHOSPHOLIPID SYNDROMEAnnual Review of Medicine, 1996
- Placental Thrombosis and Fetal Loss After Passive Transfer of Mouse Lupus Monoclonal or Human Polyclonal Anti‐Cardiolipin Antibodies in Pregnant Naive BALB/c MiceScandinavian Journal of Immunology, 1995
- Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies.Proceedings of the National Academy of Sciences, 1991
- Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).Proceedings of the National Academy of Sciences, 1990